Nuvation Bio [NUVB] vs Harmony Biosciences [HRMY] Detailed Stock Comparison

Nuvation Bio

NYSE
Loading...

Harmony Biosciences

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Nuvation Bio wins in 6 metrics, Harmony Biosciences wins in 12 metrics, with 0 ties. Harmony Biosciences appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricNuvation BioHarmony BiosciencesBetter
P/E Ratio (TTM)-1.4910.45Nuvation Bio
Price-to-Book Ratio2.882.41Harmony Biosciences
Debt-to-Equity Ratio15.4922.43Nuvation Bio
PEG Ratio0.020.04Nuvation Bio
EV/EBITDA2.615.99Nuvation Bio
Profit Margin (TTM)10.10%23.42%Harmony Biosciences
Operating Margin (TTM)-1,315.72%24.03%Harmony Biosciences
EBITDA Margin (TTM)N/A24.03%N/A
Return on Equity-44.84%27.58%Harmony Biosciences
Return on Assets (TTM)20.17%14.10%Nuvation Bio
Free Cash Flow (TTM)$-130.58M$218.67MHarmony Biosciences
1-Year Return2.95%-16.76%Nuvation Bio
Price-to-Sales Ratio (TTM)74.872.41Harmony Biosciences
Enterprise Value$524.78M$1.47BHarmony Biosciences
EV/Revenue Ratio36.561.91Harmony Biosciences
Gross Profit Margin (TTM)46.70%80.97%Harmony Biosciences
Revenue per Share (TTM)$0$14Harmony Biosciences
Earnings per Share (Diluted)$-0.38$3.10Harmony Biosciences
Beta (Stock Volatility)1.370.84Harmony Biosciences
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Nuvation Bio vs Harmony Biosciences Stock Performance Analysis

Loading Price Chart...

Nuvation Bio
Harmony Biosciences
Nuvation Bio Stock Overview | Harmony Biosciences Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Nuvation Bio-6.27%-19.49%35.34%73.48%40.18%21.24%
Harmony Biosciences-3.08%-10.00%-8.68%-2.82%-3.60%-7.01%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Nuvation Bio2.95%38.33%-71.45%-68.44%-68.44%-68.44%
Harmony Biosciences-16.76%-26.12%-3.60%-10.03%-10.03%-10.03%

News Based Sentiment: Nuvation Bio vs Harmony Biosciences

Nuvation Bio

News based Sentiment: POSITIVE

Nuvation Bio demonstrated strong early commercial traction with IBTROZI™ in Q2 2025, coupled with active investor engagement and a potential financing deal for taletrectinib. While some analyst concerns exist, the overall narrative is positive, supported by insider buying and bullish market signals.

View Nuvation Bio News Sentiment Analysis

Harmony Biosciences

News based Sentiment: POSITIVE

While the Q2 earnings slightly missed expectations, Harmony Biosciences demonstrated continued progress with its pipeline, reaffirmed its full-year guidance, and maintained strong institutional support. The company's ambitious strategic vision and positive analyst ratings suggest a positive outlook for long-term growth, making September a relatively positive month for investors.

View Harmony Biosciences News Sentiment Analysis

Performance & Financial Health Analysis: Nuvation Bio vs Harmony Biosciences

MetricNUVBHRMY
Market Information
Market Cap i$1.07B$1.86B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i8,443,260893,510
90 Day Avg. Volume i6,001,997646,440
Last Close$3.14$32.39
52 Week Range$1.54 - $4.09$26.47 - $41.61
% from 52W High-23.23%-22.16%
All-Time High$15.23 (May 24, 2021)$62.08 (Dec 05, 2022)
% from All-Time High-79.38%-47.83%
Growth Metrics
Quarterly Revenue Growth2.37%0.16%
Quarterly Earnings Growth2.37%2.43%
Financial Health
Profit Margin (TTM) i0.10%0.23%
Operating Margin (TTM) i-13.16%0.24%
Return on Equity (TTM) i-0.45%0.28%
Debt to Equity (MRQ) i15.4922.43
Cash & Liquidity
Book Value per Share (MRQ)$1.09$13.44
Cash per Share (MRQ)$1.78$9.83
Operating Cash Flow (TTM) i$-168,192,000$259.38M
Levered Free Cash Flow (TTM) i$179.17M$197.81M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Nuvation Bio vs Harmony Biosciences

MetricNUVBHRMY
Price Ratios
P/E Ratio (TTM) i-1.4910.45
Forward P/E i-4.989.94
PEG Ratio i0.020.04
Price to Sales (TTM) i74.872.41
Price to Book (MRQ) i2.882.41
Market Capitalization
Market Capitalization i$1.07B$1.86B
Enterprise Value i$524.78M$1.47B
Enterprise Value Metrics
Enterprise to Revenue i36.561.91
Enterprise to EBITDA i2.615.99
Risk & Other Metrics
Beta i1.370.84
Book Value per Share (MRQ) i$1.09$13.44

Financial Statements Comparison: Nuvation Bio vs Harmony Biosciences

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)NUVBHRMY
Revenue/Sales i$4.83M$184.73M
Cost of Goods Sold i$2.58M$31.99M
Gross Profit i$2.26M$152.74M
Research & Development i$27.36M$34.54M
Operating Income (EBIT) i$-63.59M$56.25M
EBITDA i$-58.65M$66.98M
Pre-Tax Income i$-59.01M$57.18M
Income Tax i$0$11.62M
Net Income (Profit) i$-59.01M$45.56M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)NUVBHRMY
Cash & Equivalents i$47.98M$489.00M
Total Current Assets i$475.57M$642.69M
Total Current Liabilities i$52.77M$175.12M
Long-Term Debt i$3.84M$158.18M
Total Shareholders Equity i$419.46M$720.53M
Retained Earnings i$-963.98M$47.78M
Property, Plant & Equipment i$1.53MN/A

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)NUVBHRMY
Operating Cash Flow i$-32.06M$36.44M
Capital Expenditures i$-72,000$-128,000
Free Cash Flow i$-42.70M$33.86M
Debt Repayment i$-534,000$-3.75M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricNUVBHRMY
Shares Short i68.13M4.33M
Short Ratio i15.088.35
Short % of Float i0.32%0.16%
Average Daily Volume (10 Day) i8,443,260893,510
Average Daily Volume (90 Day) i6,001,997646,440
Shares Outstanding i337.84M57.14M
Float Shares i231.05M50.63M
% Held by Insiders i0.19%0.11%
% Held by Institutions i0.67%0.95%

Dividend Analysis & Yield Comparison: Nuvation Bio vs Harmony Biosciences

MetricNUVBHRMY
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A